To investigate the efficacy and safety of compound azintamide enteric-coated tablets in the treatment of patients with functional dyspepsia.

Ninety patients with functional dyspepsia who received treatment in Department of Gastroenterology,Yuncheng Central Hospital from January 2017 to March 2019 were included in this study. They were randomly assigned to receive Eobili dispersible tablets alone (control group,n = 45) or Eobili dispersible tablets + compound azintamide enteric-coated tablets (study group, n = 45). Therapeutic effect, incidence of adverse reactions, and quality of life were compared between control and study groups.

After treatment, the total score of functional dyspepsia in the study group was (1.54 ± 0.06) points, which was lower than (2.13 ± 0.13) points in the control group (t = 3.881, P < 0.05).There was no significant difference in the incidence of adverse reactions between study and control groups (4.44% vs. 11.11%, χ²= 0.620, P > 0.05). The quality of life score in the study group was significantly lower than that in the control group [(6.34 ± 1.05) points vs. (9.98 ± 1.22) points, t = 4.826, P < 0.05].

Compound azintamide enteric-coated tablets for the treatment of functional dyspepsia exhibits good therapeutic effects through effectively decreasing the severity of functional dyspepsia, reducing the attack frequency and improving the quality of life. It is proven safe and reliable and is worthy of clinical application.

Dyspepsia; Compound azimide enteric-coated tablet; Security; Eobili dispersible tablet; Abdominal distension; Abdominal pain; Attack frequency; Adverse reactions